Cargando…

A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy

Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu-Fang, Kuo, Macus Tien, Liu, Yi-Sheng, Cheng, Ya-Min, Wu, Pei-Ying, Chou, Cheng-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544081/
https://www.ncbi.nlm.nih.gov/pubmed/31179244
http://dx.doi.org/10.3389/fonc.2019.00437
_version_ 1783423190013313024
author Huang, Yu-Fang
Kuo, Macus Tien
Liu, Yi-Sheng
Cheng, Ya-Min
Wu, Pei-Ying
Chou, Cheng-Yang
author_facet Huang, Yu-Fang
Kuo, Macus Tien
Liu, Yi-Sheng
Cheng, Ya-Min
Wu, Pei-Ying
Chou, Cheng-Yang
author_sort Huang, Yu-Fang
collection PubMed
description Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum. In the clinic, re-sensitization of platinum-resistance in relapsed EOC has been discovered by the application of trientine plus platinum (NCT01178112). However, no pharmacokinetic data of trientine has been reported in cancer patients. Purpose: Our study aimed to explore the safety and activity of trientine combined with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with EOC, tubal, and peritoneal cancer who experienced disease progression during platinum-based chemotherapy or showed relapse <12 months after completing first-line chemotherapy. Also, we aimed to demonstrate pharmacokinetic parameters and to discover potential biomarkers in our EOC patients. Methods: In this dose escalation study, 18 Asian patients in six dosing cohorts received fixed doses of carboplatin (AUC 4) and PLD (LipoDox®, TTY Biopharm Co. Ltd., Taipei, Taiwan) (40 mg/m(2), day 1 per 4-week cycle), and escalated daily trientine doses (range: 300–1800 mg; initiated 7 days before the 1st combination cycle) according to a 3 + 3 design. Results: No dose-limiting toxicity or treatment-related death was observed. Four patients (22.2%) developed grade 3 drug-related adverse events (AEs), whereas no grade 4 AEs were encountered. Anemia and grade 2 dizziness were the most common hematological toxicity and neurotoxicity, respectively. In a pharmacokinetics comparison with healthy volunteers in the literature, our patients achieved greater absorption after oral trientinem, and more rapid elimination of triethylenetetramine dihydrochloride at high doses. The clinical benefit rate was 33.3 and 50.0% in the platinum-resistant and the partially platinum-sensitive group, respectively. A high baseline serum iron level and low serum copper level might help differentiate subgroups of patients with different clinical responses. Nevertheless, no associations of the clinical response with the levels of serum hCtr1, ceruloplasmin, or copper were observed. Conclusion: Combination therapy with carboplatin, trientine, and PLD was well-tolerated and safe. Our results encourage the development of a future phase II trial. Clinical trial registration: ClinicalTrials.gov # NCT03480750.
format Online
Article
Text
id pubmed-6544081
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65440812019-06-07 A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy Huang, Yu-Fang Kuo, Macus Tien Liu, Yi-Sheng Cheng, Ya-Min Wu, Pei-Ying Chou, Cheng-Yang Front Oncol Oncology Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum. In the clinic, re-sensitization of platinum-resistance in relapsed EOC has been discovered by the application of trientine plus platinum (NCT01178112). However, no pharmacokinetic data of trientine has been reported in cancer patients. Purpose: Our study aimed to explore the safety and activity of trientine combined with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with EOC, tubal, and peritoneal cancer who experienced disease progression during platinum-based chemotherapy or showed relapse <12 months after completing first-line chemotherapy. Also, we aimed to demonstrate pharmacokinetic parameters and to discover potential biomarkers in our EOC patients. Methods: In this dose escalation study, 18 Asian patients in six dosing cohorts received fixed doses of carboplatin (AUC 4) and PLD (LipoDox®, TTY Biopharm Co. Ltd., Taipei, Taiwan) (40 mg/m(2), day 1 per 4-week cycle), and escalated daily trientine doses (range: 300–1800 mg; initiated 7 days before the 1st combination cycle) according to a 3 + 3 design. Results: No dose-limiting toxicity or treatment-related death was observed. Four patients (22.2%) developed grade 3 drug-related adverse events (AEs), whereas no grade 4 AEs were encountered. Anemia and grade 2 dizziness were the most common hematological toxicity and neurotoxicity, respectively. In a pharmacokinetics comparison with healthy volunteers in the literature, our patients achieved greater absorption after oral trientinem, and more rapid elimination of triethylenetetramine dihydrochloride at high doses. The clinical benefit rate was 33.3 and 50.0% in the platinum-resistant and the partially platinum-sensitive group, respectively. A high baseline serum iron level and low serum copper level might help differentiate subgroups of patients with different clinical responses. Nevertheless, no associations of the clinical response with the levels of serum hCtr1, ceruloplasmin, or copper were observed. Conclusion: Combination therapy with carboplatin, trientine, and PLD was well-tolerated and safe. Our results encourage the development of a future phase II trial. Clinical trial registration: ClinicalTrials.gov # NCT03480750. Frontiers Media S.A. 2019-05-24 /pmc/articles/PMC6544081/ /pubmed/31179244 http://dx.doi.org/10.3389/fonc.2019.00437 Text en Copyright © 2019 Huang, Kuo, Liu, Cheng, Wu and Chou. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Huang, Yu-Fang
Kuo, Macus Tien
Liu, Yi-Sheng
Cheng, Ya-Min
Wu, Pei-Ying
Chou, Cheng-Yang
A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
title A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
title_full A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
title_fullStr A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
title_full_unstemmed A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
title_short A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
title_sort dose escalation study of trientine plus carboplatin and pegylated liposomal doxorubicin in women with a first relapse of epithelial ovarian, tubal, and peritoneal cancer within 12 months after platinum-based chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544081/
https://www.ncbi.nlm.nih.gov/pubmed/31179244
http://dx.doi.org/10.3389/fonc.2019.00437
work_keys_str_mv AT huangyufang adoseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT kuomacustien adoseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT liuyisheng adoseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT chengyamin adoseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT wupeiying adoseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT chouchengyang adoseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT huangyufang doseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT kuomacustien doseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT liuyisheng doseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT chengyamin doseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT wupeiying doseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy
AT chouchengyang doseescalationstudyoftrientinepluscarboplatinandpegylatedliposomaldoxorubicininwomenwithafirstrelapseofepithelialovariantubalandperitonealcancerwithin12monthsafterplatinumbasedchemotherapy